BackAbCellera Biologics Overview
AbCellera Biologics Inc

AbCellera Biologics Target Price

Analysts' average 12-month price target for AbCellera Biologics is $8.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.34

Average Target Price

$8.0014.3% downside

3 analysts in the last 4 months

High: $9 | Low: $7

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06Stifel Nicolaus$93.6% downsideOpen
2026-05-12Stifel Nicolaus$814.3% downsideOpen
2026-05-05Cantor Fitzgerald$725.1% downsideOpen
2024-11-05BMO CapitalGary Nachman$546.5% downsideOpen
2024-08-23KeyBancScott Schoenhaus$546.5% downsideOpen
2024-05-08KeyBancScott Schoenhaus$725.1% downsideOpen
2023-01-06Leerink Partners$1892.7% upsideOpen
2022-12-15Goldman SachsAndrea Tan$30221.2% upsideOpen
2022-11-16Truist Financial$29210.5% upsideOpen
2022-08-10Credit Suisse$34264% upsideOpen

AbCellera Biologics (ABCL) FAQ

AbCellera Biologics's target price stands at $8. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $8 for ABCL implies 14.3% downside versus today's price ($9.34). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how AbCellera Biologics's target price evolved across reporting periods, while the comparison chart places ABCL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.